Taken together, our study provides new information supporting the hypothesis that specific ANGPT2, TEK, VEGF, and VEGFR2 variants may contribute to poor treatment results and survival in HNSCC. This evidence concerns the gene VEGFA and head and neck squamous cell carcinoma.